Dr Pirkko-Liisa Kellokumpu-Lehtinen speaks to ecancer about adjuvant docetaxel versus surveillance in intermediate- or high-risk prostate cancer after radical curative radiotherapy: the final 10-year survival results of the SPCG-13 trial.

Dr Kellokumpu-Lehtinen talks about two studies that focused on high-risk patients receiving local radical radiotherapy, comparing surveillance with docetaxel.

While quality of life initially declined during treatment, it improved after a year.

Ten-year survival rates showed no significant advantage for docetaxel, highlighting the need for better predictive markers to select early prostate cancer patients for adjuvant treatments.